← board
GLAXF
distress 1/10 · well-funded / low risk$25.760%today-18% from 52w high
Revenue
$7629M
Liquidity
$3443M
Runway
—
Shares 1y
0%
Price & events
+4.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.4%
1W
+0.2%
1M
-5.3%
3M
+4.0%
6M
+39.0%
1Y
+42.4%
2Y
+29.7%
5Y
+38.6%
All
Overview
- Market Cap
- $111.17B
- Enterprise Value
- $121.74B
- Volume
- 0
- 52 Week Range
- $17.15 – $31.48
- Total Shares
- 4.32B
- Float Shares
- 3.89B
- % Held by Insiders
- 1.75%
- % Held by Institutions
- 47.41%
- Beta
- 0.30
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-07-28Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 4,315,445,026 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-18JP Morgan Cazenove Reiterates GSK (GLAXF) Underweight Recommendation - MSN
- 2026-06-25Is GSK Quietly Becoming An Oncology Powerhouse (NYSE:GSK) - Seeking Alpha
- 2026-04-19GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential (NYSE:GSK) - Seeking Alpha
- 2026-03-31GSK: Chinese Expansion And Fine Financials (NYSE:GSK) - Seeking Alpha
- 2026-03-18GSK Expanding Fast—Oncology, HIV, and Smart Acquisitions (NYSE:GSK) - Seeking Alpha
- 2026-02-17GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) (NYSE:GSK) - Seeking Alpha
- 2026-01-20RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate (RAPT) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.